HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM LIVTENCITY®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052. Failure to submit clinical documentation to support this request will result in a dismissal of the request. If you have prior authorization questions, please call for assistance: 385-425-5094 Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements. ID#: Date: Member Name: DOB: Gender: Physician: Office Phone: Office Fax: Office Contact: Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. **Product being requested:** ☐ Livtencity® (maribavir) Dosing/Frequency: If the request is for reauthorization, proceed to reauthorization section. Questions Yes No **Comments/Notes** CYTOMEGALOVIRUS (CMV) WITH POST-TRANSPLANT CMV INFECTION/DISEASE 1. Is the member 12 years of age or older? 2. Does the member weigh at least 35 kg? Please provide documentation 3. Is the requesting provider an infectious disease specialist, hematologist, oncologist, or transplant specialist? 4. Is the member a recipient of hematopoietic stem cell or solid Please provide documentation

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Please provide documentation

Please provide documentation

organ transplant?

7. Is the member pregnant?

5. Has the member tried and failed, or have a contraindication,

6. Is the member on any other CMV antivirals?

intolerance, or resistance to all of the following medications:Ganciclovir or valganciclovir, foscarnet, and cidofovir

Additional information:
Physician Signature:

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy PHARM-HU-127 Origination Date: 12/17/2021 Reviewed/Revised Date: 01/19/2022 Next Review Date: 01/19/2023 Current Effective Date: 02/01/2022

Confidentiality Notice